Singapore: According to a new regulatory filing, WuXi PharmaTech one of China's leading drugmaker, is planning to raise $250 million to invest in healthcare and life sciences startups in the US and China.
"WuXi Healthcare Ventures Fund II is being formed to invest in significant equity stakes in the U.S. and China," the company reported in its annual report.
WuXi had earlier also mentioned a capital commitment of $50 million in its first corporate venture fund, launched in 2011 with a focus on technology and life science companies.
